About
Caris Life Sciences sits at the intersection of molecular biology, data science, and artificial intelligence to revolutionize cancer care. Founded in 2008, Caris provides physicians, patients, and biopharma companies with deeply comprehensive cancer diagnostics through tissue and blood profiling across DNA, RNA, and protein biomarkers. Their core offerings include tissue profiling products—MI Profile, MI Cancer Seek, and MI Tumor Seek Hybrid—alongside the Caris Assure liquid biopsy for blood-based cancer detection. Building on this molecular data foundation, Caris offers proprietary AI signature products including Caris GPSai and Caris FOLFIRSTai, which deliver predictive insights on treatment benefit or harm for specific patient populations, such as NSCLC chemotherapy guidance. The Caris CODEai and Nanoverse platforms power next-generation research into multimodal molecular data, while the Molecular Tumor Board connects physicians with expert consultation for complex cases. The Right-In-Time Trials program matches patients—including historically underserved populations—to relevant clinical trials based on their molecular profile. For biopharma partners, Caris accelerates drug discovery, translational medicine, and commercialization through its vast molecular data repository and clinical trial matching infrastructure. With a growing portfolio of publications, AI innovations, and EHR integrations, Caris is positioned as a leading TechBio company transforming how cancer is detected, categorized, and treated at the molecular level.
Key Features
- Comprehensive Tissue Profiling: MI Profile, MI Cancer Seek, and MI Tumor Seek Hybrid analyze DNA, RNA, and proteins from tumor samples to create a complete molecular blueprint for each patient.
- Blood-Based Cancer Diagnostics: Caris Assure offers liquid biopsy testing that detects cancer biomarkers from blood, enabling minimally invasive tumor profiling and treatment monitoring.
- AI-Powered Molecular Signatures: Proprietary AI models including Caris GPSai and Caris FOLFIRSTai predict treatment outcomes, helping oncologists identify which therapies will benefit or harm specific patients.
- Right-In-Time Clinical Trial Matching: Automatically matches patients to relevant clinical trials based on their molecular profile, expanding access to precision oncology research for diverse patient populations.
- Biopharma Multimodal Data & Discovery: Provides biopharma partners with vast molecular datasets, Caris Discovery tools, and clinical trial infrastructure to accelerate drug development and commercialization.
Use Cases
- An oncologist orders a Caris MI Profile on a newly diagnosed cancer patient to identify targetable mutations and select the most effective first-line therapy.
- A cancer patient with limited tissue sample availability undergoes Caris Assure liquid biopsy to obtain a comprehensive molecular profile from a blood draw.
- A biopharma company uses Caris's multimodal molecular data and clinical trial matching tools to identify the right patient population for a Phase II oncology drug trial.
- A multidisciplinary cancer team consults the Caris Molecular Tumor Board to obtain expert interpretation of complex genomic findings for a rare tumor type.
- An underserved cancer patient is matched to a relevant clinical trial through Right-In-Time Trials based on their unique molecular profile, gaining access to cutting-edge precision therapies.
Pros
- Holistic Molecular Coverage: Profiles across DNA, RNA, and protein layers simultaneously, providing a more complete picture of tumor biology than single-biomarker tests.
- Clinically Actionable AI Insights: AI signature products translate complex molecular data into clear treatment guidance, reducing the interpretive burden on oncologists.
- End-to-End Oncology Ecosystem: Serves patients, physicians, and biopharma from a single platform—covering diagnostics, expert consultation, clinical trial access, and drug discovery.
- Expanding Trial Access for Underserved Patients: Right-In-Time Trials actively addresses health equity by connecting historically underserved cancer patients to relevant clinical trials.
Cons
- Requires Physician Ordering: Patients cannot directly order Caris tests; all testing must be initiated through a licensed oncologist or physician, limiting direct access.
- Enterprise and Clinical Focus: The platform is designed for healthcare institutions and biopharma enterprises, making it inaccessible to general consumers or small research teams.
- Cost and Insurance Complexity: Advanced molecular profiling tests can be expensive, and coverage varies by insurer, which may create financial barriers for some patients despite financial services support.
Frequently Asked Questions
What is molecular tumor profiling and why does it matter?
Molecular tumor profiling analyzes the DNA, RNA, and proteins in a patient's cancer to identify specific biomarkers and mutations driving tumor growth. This information helps oncologists select therapies most likely to be effective for that individual patient, moving beyond one-size-fits-all treatment approaches.
Who can order Caris Life Sciences tests?
Caris tests are ordered by licensed physicians, typically oncologists. Patients interested in Caris profiling should speak with their treating physician or use the 'Find a Doctor' resource on the Caris website to locate a physician familiar with molecular testing.
What is Caris Assure and how does it differ from tissue testing?
Caris Assure is a blood-based (liquid biopsy) test that detects cancer biomarkers from a simple blood draw, making it less invasive than traditional tissue biopsies. It is particularly useful for monitoring treatment response or when tumor tissue is difficult to obtain.
How does Caris use artificial intelligence in its diagnostics?
Caris has developed proprietary AI models—such as Caris GPSai and Caris FOLFIRSTai—that analyze multimodal molecular data to predict which treatments will benefit or potentially harm specific patients. For example, Caris FOLFIRSTai identifies NSCLC patients who may gain or be harmed by the addition of chemotherapy.
How can biopharma companies partner with Caris Life Sciences?
Biopharma companies can leverage Caris's molecular profiling capabilities, multimodal data repository, clinical trial matching infrastructure, and Caris Discovery platform to accelerate drug discovery, translational research, and commercialization of oncology therapeutics.
